Skip to main content

Table 3 Comparison of clinical data.

From: Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms

 

Before TCA

After TCA

F

EDSS – score

6.44 ± 1.06; 3.5 – 6.5

5.47 ± 1.24; 2 – 8.5

379.28

walking distance

158.03 ± 501.20; 0 – 5000

439.38 ± 895.24; 0 – 5000

34.40

Barthel index

58 ± 20.07; 5 – 100

89.13 ± 12.57; 60 – 100

347.52

P2 (tibial nerve)

105.80 ± 10.38; 85 – 130

88.57 ± 5.60; 77 – 106

470.96

N2 (tibial nerve)

118.83 ± 10.49; 92 – 148

101.63 ± 6.43; 80 – 118

425.71

P3 (tibial nerve)

131.79 ± 13.22; 70 – 164

114.31 ± 7.46; 95 – 135

325.88

N2 (median nerve)

46.53 ± 5.40; 23–60

41.03 ± 2.92; 23–47

138.10

P2 (median nerve)

52.73 ± 6.34; 25 – 68

47.09 ± 3.03; 41–56

128.80

  1. All data are given as mean ± standard deviation; minimum – maximum in the second and third column; latencies (N2, P2, P3) of the somatosensensory evoked potentials are given in milliseconds, walking distance is given in meters, F = F-value of ANCOVA, SD = standard deviation; TCA = standardized intrathecal triamcinolon acetonide application according to the methods section.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us